"Recombinant Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins prepared by recombinant DNA technology.
| Descriptor ID |
D011994
|
| MeSH Number(s) |
D12.776.828
|
| Concept/Terms |
Recombinant Proteins- Recombinant Proteins
- Proteins, Recombinant
- Proteins, Biosynthetic
- Biosynthetic Proteins
Proteins, Recombinant DNA- Proteins, Recombinant DNA
- DNA Proteins, Recombinant
- Recombinant DNA Proteins
- DNA Recombinant Proteins
- Proteins, DNA Recombinant
- Recombinant Proteins, DNA
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Proteins".
This graph shows the total number of publications written about "Recombinant Proteins" by people in this website by year, and whether "Recombinant Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 39 | 40 |
| 1997 | 1 | 29 | 30 |
| 1998 | 0 | 35 | 35 |
| 1999 | 2 | 34 | 36 |
| 2000 | 2 | 45 | 47 |
| 2001 | 1 | 23 | 24 |
| 2002 | 1 | 40 | 41 |
| 2003 | 3 | 40 | 43 |
| 2004 | 0 | 35 | 35 |
| 2005 | 2 | 33 | 35 |
| 2006 | 1 | 23 | 24 |
| 2007 | 1 | 17 | 18 |
| 2008 | 2 | 21 | 23 |
| 2009 | 0 | 19 | 19 |
| 2010 | 4 | 21 | 25 |
| 2011 | 1 | 23 | 24 |
| 2012 | 2 | 13 | 15 |
| 2013 | 2 | 21 | 23 |
| 2014 | 0 | 15 | 15 |
| 2015 | 4 | 16 | 20 |
| 2016 | 2 | 8 | 10 |
| 2017 | 2 | 11 | 13 |
| 2018 | 2 | 17 | 19 |
| 2019 | 0 | 10 | 10 |
| 2020 | 1 | 6 | 7 |
| 2021 | 1 | 13 | 14 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Proteins" by people in Profiles.
-
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes. Eur J Endocrinol. 2025 Jul 31; 193(2):310-319.
-
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. Clin Cancer Res. 2025 Jan 17; 31(2):299-307.
-
Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia. J Stroke Cerebrovasc Dis. 2024 Jun; 33(6):107310.
-
Self-assembling amyloid-like nanostructures from SARS-CoV-2 S1, S2, RBD and N recombinant proteins. Arch Biochem Biophys. 2024 02; 752:109843.
-
Acetylation of fission yeast tropomyosin does not promote differential association with cognate formins. Cytoskeleton (Hoboken). 2023 03; 80(3-4):77-92.
-
Effect of Thrombin and Incubation Time on Porcine Whole Blood Clot Elasticity and Recombinant Tissue Plasminogen Activator Susceptibility. Ultrasound Med Biol. 2022 08; 48(8):1567-1578.
-
Targeting of Silver Cations, Silver-Cystine Complexes, Ag Nanoclusters, and Nanoparticles towards SARS-CoV-2 RNA and Recombinant Virion Proteins. Viruses. 2022 04 26; 14(5).
-
Filgrastim, fibrinolysis, and neovascularization. J Tissue Eng Regen Med. 2022 05; 16(5):496-510.
-
(More than) doubling down: Effective fibrinolysis at a reduced rt-PA dose for catheter-directed thrombolysis combined with histotripsy. PLoS One. 2022; 17(1):e0261567.
-
The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocr Disord. 2021 Nov 20; 21(1):232.